8.00 Check-In & Morning Coffee
8:50 am Chair’s Opening Remarks
Achieving an Asian Decentralized Manufacturing Platform to Support Development of mRNA Vaccines for Emerging Health Threats & Future Pandemics
9:00 am Establishing a Two-Track Strategy & Platform Technology Required for Next Pandemic Preparedness
Synopsis
- Advancing decentralized manufacturing
- Developing extra long-term storage
- Combating pandemic preparedness
9:30 am Building a Decentralized & Accelerated mRNA Vaccine Production System (DeCAFx) for Pandemic Preparedness
Synopsis
- DeCAFx, led by IVI, is a decentralized, modular mRNA manufacturing platform for rapid, regional pandemic response
- Collaborating globally on mRNA R&D, including vaccines for Lassa and Rift Valley fevers, saRNA, and novel delivery methods
- Aligning with CEPI’s 100 Days Mission, DeCAFx aims to enable vaccine rollout within weeks of pathogen detection
10:00 am Innovative Cap Analog Design Advancing mRNA-Based Therapeutics
Synopsis
- Cap analogs are essential components in in vitro–transcribed (IVT) mRNA synthesis, as they provide the 5′ cap structure critical for both stability and efficient translation. Moreover, cap structures help reduce immunogenicity by mimicking natural eukaryotic mRNA and preventing recognition by innate immune sensors such as RIG-I and MDA5. This is particularly important for therapeutic applications, where minimizing unwanted immune activation is key to safety and efficacy
- To further address the challenge of mRNA immunogenicity, we developed a series of novel cap analogs, termed HixCap. Designed through a rational approach, these structures are predicted to evade binding by IFIT1, an interferon-stimulated gene product known to interact with Cap0 and Cap1 and suppress mRNA translation. Our in vitro and in vivo studies demonstrate that HixCap analogs enhance mRNA translation efficiency, particularly under conditions where interferon responses are activated
- Collectively, these findings highlight the potential of next-generation cap analogs to improve the performance of mRNA therapeutics and support the advancement of more effective mRNA vaccines against infectious diseases
10.00 Morning Break & Networking
11:15 am Panel Discussion – Fighting the Next Pandemic with mRNA Technology & Equitable Vaccine Supply Chain for Commercial Markets in Asia
Synopsis
With the Korean Disease Control and Prevention Agency’s mission to invest in the best mRNA technologies to fight the next
pandemic, it’s more important than ever to establish collaborations between Korean and international partners to support
regional and global health through establishment of local manufacturing of vaccine in LMICs
Hear from vaccine experts as they shed light on strategies to overcome the next pandemic through RNA technology innovations.
- How to develop key biopharma partnerships to achieve the impact on global vaccine equity
- How to leverage best practices for mRNA vaccine R&D and local manufacturing
- Outlining current bottlenecks with scaling up to ensure regional capacity and global availability of mRNA vaccines
11:50 am Session Reserved for 4basebio
12:00 pm Thermostable mRNA Vaccines using Hybrid Polymer-Lipid Nanoparticles
Synopsis
- Presenting a polymer-based nanoparticles for vaccines and therapeutics
- Highlighting 12-month stability data of liquid formulations at 2 – 80°C and improvements related to anti-PEG antibodies and response durability
- Outlining a CEPI funded rabies mRNA vaccine program
12:30 pm Showcasing Recent Progress in mRNA-Based Targeted Protein Degrader Development
Synopsis
- Presenting an update of EPDegTM bioPROTAC development
- Demonstrating proved differentiating points of bioPR
1.00 Lunch Break & Networking
Successfully Targeting Extra-Hepatic Tissues with Novel RNA Platforms Enhancing Stability, Potency & Delivery
2:00 pm Advancing mRNA/LNP Platform Technology for Innovative Vaccines & Therapeutics
Synopsis
- Showcasing a novel mRNA platform technology
- Presenting a unique LNP platform technology
- Outlining key applications of mRNA vaccine & therapeutics
2:30 pm Pioneering Next-Generation RNA–LNP Platforms & Applications
Synopsis
- Enhancing efficacy and safety in RNA delivery with novel ionizable lipid–based LNPs
- Targeting extra-hepatic delivery, including the spleen and lungs, with novel targeted LNPs
- Demonstrating effective applications in saRNA vaccines and mRNA therapeutics
3:00 pm Advancing Antibody Therapeutics Through In Vivo mRNA-LNP Delivery
Synopsis
- Presenting a novel mRNA-LNP platform optimized for in vivo expression of therapeutic antibodies, including bispecific antibodies
- Exploring therapeutic antibody potential from discovery to pre-clinical development
- Overcoming key challenges of in vivo protein expression for successful translation of mRNA-based therapeutics
3:30 pm Progressing mRNA-LNP Powered Protein Replacement Therapy for Inherited Metabolic Diseases
Synopsis
- Showcasing Innorna’s diversity-oriented lipid library
- Highlighting a preclinical efficacy study of mRNA-based protein replacement therapy for inherited metabolic diseases
- Demonstrating effective LNP delivery beyond the liver
4.00 Afternoon Break & Networking
The Next Wave: Advancing Next Generation RNA Technologies to Achieve Better Dosing & Safety in Patients
4:30 pm The Opportunities for Chinese Genetic Medicine
Synopsis
- Overview of Chinese genetic medicine development
- Current development on technology platforms and products
- AnlongBio's exploration on siRNA technologies
5:00 pm Targeting lncRNA TUG1 for Treatment of Patients with GBM by Using a Novel DDS for ASO – New Data
Synopsis
- Presenting a novel drug delivery system for antisense oligonucleotides
- Achieving success in non-clinical experiments
- Showcasing early clinical results